Treatment Compliance in Children and Adolescents on ADHD Medication

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary research objective of this observational study is to evaluate treatment compliance over one year in children and adolescents who are newly initiated on medication approved for the treatment of ADHD in a routine clinical setting. Compliance will be assessed using the Pediatric Compliance Self-Rating (PCSR) Instrument. A patient will be considered as compliant at a given visit, if the PCSR score is at least 5, corresponding to taking the medication at least often.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Atomoxetine Hydrochloride; Central Nervous System Stimulants

Criteria

Inclusion Criteria:

• 6-17 years old

• diagnosis of ADHD according to ICD-10 or DSM-IV criteria

• new initiation onto an approved medication to treat ADHD

Exclusion Criteria:

• no specific exclusion criteria